Insys Therapeutics (INSY) Tops Q4 EPS by 3c

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $54.9 million versus the consensus estimate of $51.15 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41